In the News

Stem Cell Theranostics and CapellaBio Announce Cardio-Oncology Collaboration and Discovery of a Novel Class of Cardioprotective Drug Therapies

Admin • CCON • 12/16/2015

REDWOOD CITY, Calif. and PALO ALTO, Calif., Dec. 16, 2015 /PRNewswire/ — Stem Cell Theranostics (SCT) and CapellaBio announced today that they have established a cardio-oncology collaboration to discover novel drug therapies to prevent... Read more »

Read More...

Cardiac Meds Appear to Protect Heart From Herceptin Damage

Admin • CCON • 12/15/2015

SAN ANTONIO ― Breast cancer patients treated with trastuzumab (Herceptin, Genentech, Inc) had significantly lower risk for left ventricular (LV) dysfunction and consequent treatment interruptions when treated prophylactically with heart... Read more »

Read More...

KU hospital program promotes heart health for cancer patients

Admin • CCON • 12/14/2015

KANSAS CITY, Kan. —A program at the University of Kansas Hospital is now combining cardiology and oncology. Read More

Read More...

Mixed Results for Herceptin Cardiotoxicity Prevention

Admin • CCON • 12/10/2015

Neither a beta-blocker nor an angiotensin-converting enzyme (ACE) inhibitor, used as prophylaxis against trastuzumab’s (Herceptin) adverse cardiac effects, successfully prevented left ventricle remodelling in breast cancer patients in a randomized... Read more »

Read More...

Prophylactic Heart Failure Pharmacotherapy Is Safe and Effective in Patients With HER2-overexpressing Breast Cancer

Admin • CCON • 12/9/2015

SAN ANTONIO, TX—Results from the MANTICORE trial include prophylactic use of standard heart failure (HF) pharmacotherapy prevents trastuzumab-associated left ventricular ejection fraction (LVEF) and reduces treatment interruptions due to left... Read more »

Read More...

Can cancer itself damage the heart?

Admin • CCON • 12/3/2015

Research presented today at EuroEcho-Imaging 2015 raises the possibility that cancer itself may damage heart muscle irrespective of exposure to cancer drug therapies. Researchers from the UK’s first dedicated cardio-oncology... Read more »

Read More...

Harwich Port woman blindsided by chemotherapy

Admin • CCON • 11/29/2015

Breast cancer was a devastating diagnosis for Kathleen Mingle, a teacher who played tennis, ran and generally led an active and fit life. But the shock was compounded when she... Read more »

Read More...

CCC 2015: Improving Cardiac Care for Cancer Patients

Admin • CCON • 11/19/2015

CCS Position Statement Dr. Dent, co-founder of the Ottawa Cardiology-Oncology Clinic at The Ottawa Hospital, led the session presenting the Canada Cardiovascular Society’s (CCS) first position statement on cardiovascular complications... Read more »

Read More...

NIH Funding Opportunity: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R21)

Admin • CCON • 11/17/2015

This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to... Read more »

Read More...

AHA: Candesartan May Preserve Cardiac Function in Breast Ca Patients

Admin • CCON • 11/11/2015

ORLANDO — An angiotensin II receptor blocker may help to preserve cardiac function in patients receiving treatment for breast cancer, according to results of a small trial reported here. Read... Read more »

Read More...